Difluoromethylornithine Is a Novel Inhibitor of Helicobacter pylori Growth, CagA Translocation, and Interleukin-8 Induction by Barry, Daniel P. et al.
Difluoromethylornithine Is a Novel Inhibitor of
Helicobacter pylori Growth, CagA Translocation, and
Interleukin-8 Induction
Daniel P. Barry
1,3, Mohammad Asim
1,3, David A. Leiman
1, Thibaut de Sablet
1,3, Kshipra Singh
1,3,
Robert A. Casero Jr.
4, Rupesh Chaturvedi
1,3, Keith T. Wilson
1,2,3*
1Division of Gastroenterology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, 2Department of Cancer
Biology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, 3Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee,
United States of America, 4Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland,
United States of America
Abstract
Helicobacter pylori infects half the world’s population, and carriage is lifelong without antibiotic therapy. Current regimens
prescribed to prevent infection-associated diseases such as gastroduodenal ulcers and gastric cancer can be thwarted by
antibiotic resistance. We reported that administration of 1% D,L-a-difluoromethylornithine (DFMO) to mice infected with H.
pylori reduces gastritis and colonization, which we attributed to enhanced host immune response due to inhibition of
macrophage ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis. Although no ODC has
been identified in any H. pylori genome, we sought to determine if DFMO has direct effects on the bacterium. We found that
DFMO significantly reduced the growth rate of H. pylori in a polyamine-independent manner. Two other Gram-negative
pathogens possessing ODC, Escherichia coli and Citrobacter rodentium, were resistant to the DFMO effect. The effect of
DFMO on H. pylori required continuous exposure to the drug and was reversible when removed, with recovery of growth
rate in vitro and the ability to colonize mice. H. pylori exposed to DFMO were significantly shorter in length than those
untreated and they contained greater internal levels of ATP, suggesting severe effects on bacterial metabolism. DFMO
inhibited expression of the H. pylori virulence factor cytotoxin associated gene A, and its translocation and phosphorylation
in gastric epithelial cells, which was associated with a reduction in interleukin-8 expression. These findings suggest that
DFMO has effects on H. pylori that may contribute to its effectiveness in reducing gastritis and colonization and may be a
useful addition to anti-H. pylori therapies.
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Introduction
Helicobacter pylori is a Gram-negative bacterial pathogen that
selectively colonizes the human stomach. It infects more than 50%
of the world’s population and is the causative agent of disorders
that arise from the resulting chronic inflammation, ranging from
dyspepsia and gastritis to gastric and duodenal ulcers [1]. It is also
strongly associated with development of gastric cancer, the second
most common cause of cancer death [2]. H. pylori infection usually
occurs early in life and although there is an immune response
elicited by the organism, it is insufficient to eliminate the bacteria.
Infection therefore generally persists for the lifetime of the host,
though cure is possible with antimicrobial therapy. The current
standard of care prescribed to eliminate H. pylori–concurrent
administration of a proton pump inhibitor and two antibiotics–is
not effective for all patients, and in some regions eradication rates
can be as poor as 50% [3,4,5]. As antibiotic resistance is
continually rising, novel chemotherapeutic agents are of interest.
We recently reported that chronic administration of 1% (w/v)
D,L-a-difluoromethylornithine (DFMO) in the drinking water to
miceinfected withH.pyloriSS1ledtoareductioninboththelevelof
colonization and the severity of gastritis [6]. DFMO is an analogue
of the amino acid ornithine, which in eukaryotes and many bacteria
is a substrate of ornithine decarboxylase (ODC), the enzyme
responsible for catalyzing the conversion of the amino acid into the
polyamine putrescine, which can then be converted to the
polyamines spermidine and spermine by specific synthases. As
such, DFMO serves as an irreversible inhibitor of ODC [7].
Polyamines are polycationic molecules present in all living
organisms that are essential for the synthesis of macromolecules
(e.g. DNA, RNA and protein) [8,9,10]. The pathways of polyamine
biosynthesis are well-understood for eukaryotes and for the model
bacterial species Escherichia coli [11], but the full mechanisms of
polyamine production in H. pylori have not been described and no
sequenced strain possesses an ODC [12,13,14,15]. However,
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investigated whether DFMO has any direct effect on H. pylori that
could account, at least in part, for its effectiveness in reducing
inflammation and bacterial load in infected mice.
We now report that growth of H. pylori in broth cultures
supplemented with 1% DFMO was substantially inhibited and
that the generation time was nearly doubled, but that the effects of
DFMO were not associated with alterations in polyamine levels
and could not be reversed with polyamine supplementation. In
addition, exposure to DFMO induced a morphological change in
the bacteria, such that they appeared closer to a coccoid form, and
also caused elevated intracellular levels of ATP. In gastric
epithelial cells, the prototypical inflammatory response to H. pylori
infection is the induction of the neutrophil chemoattractant IL-8
[16,17], which has been associated with injection of the product of
the H. pylori gene cytotoxin associated gene (cag) A, namely CagA,
into these cells by a type IV secretion system (T4SS), followed by
its phosphorylation [18]. We now demonstrate that H. pylori
exposed to DFMO for only 12 h showed a marked reduction of H.
pylori CagA protein expression as well as less translocation of CagA
and decreased phospho-CagA within human gastric epithelial
cells. Moreover, DFMO-treated bacteria exhibited a reduced
ability to induce mRNA expression and secretion of IL-8 in these
cells. These studies indicate that direct effects of DFMO on H.
pylori may be important for the drug’s effectiveness in vivo and that
polyamine-independent effects of DFMO mediate its effects on the
bacterium.
Materials and Methods
Bacterial cultures
H. pylori strains SS1 [19] and 60190 [20] were maintained by
passage on plates of tryptic soy agar containing 5% sheep blood, as
described [21]. Prior to experiments, bacteria were grown
overnight in Brucella broth supplemented with 10% FBS in
upright 25-cm
2 tissue culture flasks at 37uC with 5% CO2 at 120
rpm. E. coli and Citrobacter rodentium were maintained on LB plates
and starter cultures were grown overnight in LB broth at 37uCa t
200 rpm, or with no agitation, respectively [22,23].
Bacterial growth curves
Overnight starter cultures of H. pylori were used to inoculate
new Brucella broth cultures at 0.1 OD600. Bacterial growth was
monitored by optical density for 24 h. To quantify viable bacteria,
culture samples were diluted and plated and colonies were counted
once visible. Some cultures were supplemented with DFMO,
ornithine, putrescine, or spermidine alone or in combination and
differences in growth were measured. As addition of DFMO
slightly acidified the media, all were adjusted with sodium
hydroxide to a pH of ,6.9 and filter sterilized prior to inoculation
with bacteria. We also measured the growth of H. pylori in F12
medium supplemented with 10% FBS and 2 mM glutamine. The
effect of DFMO on C. rodentium and E. coli was determined in LB
broth cultures begun at 0.05 OD600 and bacterial growth was
monitored by optical density.
Ornithine decarboxylase activity assay
To determine if H. pylori possessed any unrecognized ODC
activity, bacteria were grown for 6 h in Brucella broth with or
without 1% DFMO supplementation and then lysed by sonication
in buffer consisting of 50 mM Tris (pH 7.5), 2.5 mM dithiothre-
itol, 1 mM EDTA and 40 mM pyridoxal 59-phosphate. ODC
activity was measured by radiometric analysis of
14CO2 liberated
from L-[
14C]ornithine, as described previously [24]. E. coli, which
are known to possess an ODC, were grown for 6 h in LB and
treated in the same way to serve as a positive control.
Polyamine measurement
H. pylori were grown in broth with or without 1% DFMO
supplementation. Samples of growth medium and bacteria were
taken over the 12 h time course. Broth samples were centrifuged
to remove bacteria and frozen until analysis. Equal numbers of
bacteria (1610
7 estimated from OD600) were washed multiple
times in phosphate buffered saline and then resuspended and
frozen in lysis buffer (2 mM DTT, 2 mM EDTA, 10% glycerol,
1% Triton X-100, 25 mM Trizma-HCl, pH 8.0). Polyamine levels
in growth media and bacterial lysates were determined by
precolumn dansylation reverse phase high performance liquid
chromatography as reported previously [25,26].
Mouse infection
Male C57BL/6 mice aged 6–8 weeks were infected as described
[6,24,27]. Briefly, H. pylori SS1 were grown for 12 h with or
without 1% DFMO and 5610
8 bacteria were delivered intragas-
trically on days 0, 2 and 4. After one month, mice were sacrificed
and colonization was determined by serial dilution and plating of
gastric homogenates. After one week colonies were counted to
determine bacterial load. This study was carried out following
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee of Vanderbilt University (Protocol Number V/07/
247).
H. pylori morphological assessment
Experiments were performed to determine the permanence of
the inhibitory properties of DFMO on H. pylori. Brucella broth
cultures were started with or without DFMO. After 6 or 12 h of
growth, the cultures were collected and pelleted by centrifugation.
The bacteria were then resuspended in media with or without
DFMO such that four different growth conditions resulted.
Growth was monitored by optical density. In addition, bacterial
morphology was determined using Gram stain to monitor changes
induced by exposure to DFMO. To more precisely quantify size
variations, transmission electron microscopy (TEM) was used.
Culture aliquots were removed, pelleted by centrifugation and
washed in PBS. The bacteria were then fixed with 2.5%
gluteraldehye and then washed in 0.1 M sodium cacodylate
buffer. The samples were postfixed in 1% aqueous osmium
tetroxide, dehydrated through a graded series of ethanols to 100%
ethanol, and then embedded in Spurr Resin. Thin sections of the
resin-embedded material were examined using a Philips CM-12
high-resolution transmission electron microscope and images were
captured by a CCD camera at 11,500X magnification. The size of
the bacteria was determined by analyzing the images with NIH
ImageJ (version 1.41o) to measure the area of identified H. pylori.
Briefly, the threshold command was used to separate bacteria from
the background and the two-dimensional area of each cell was
calculated in mm
2 [28].
ATP assay
The CellTiter-Glo assay (Promega) was used to determine the
relative amount of ATP present in bacteria over the course of
growth as an indicator of metabolic activity. H. pylori SS1 were
grown in Brucella broth with or without DFMO and then
analyzed. Briefly, a volume of bacteria was removed, pelleted, and
washed multiple times in phosphate buffered saline. The bacteria
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2 mM EDTA, 10% glycerol, 1% Triton X-100, 25 mM Trizma-
HCl, pH 8.0) and luminescence proportional to ATP level was
assayed according to the kit’s instructions. Levels per mL of culture
were calculated, as were levels per 10
6 bacteria using the measured
optical density at each time point.
Gene expression in epithelial cells
IL-8 mRNA was measured in AGS epithelial cells exposed to H.
pylori 60190. AGS cells were grown in F12 medium supplemented
with 10% FBS and 2 mM glutamine. H. pylori from a starter
culture were grown for 12 h with or without exposure to DFMO
at which time the bacteria were collected and washed with PBS. In
6-well plates, 5610
5 AGS cells per well were infected with H. pylori
at a multiplicity of infection (MOI) of 200 bacteria per cell or were
uninfected for a negative control. Total RNA was isolated 4 h
after exposure, using TriZOL (Invitrogen), and cDNA was
synthesized from 1 mg RNA, as described [29]. Real-time PCR
was performed in a LightCycler 480 (Roche). Relative gene
expression was calculated from second derivative maximum values
using b-actin as a reference gene. IL-8 primers were 59-
TAGCAAAATTGAGGCCAAGG-39 and 59-AAACCAAGGCA-
CAGTGGAAC-39. b-actin primers were as described previously
[24].
IL-8 protein expression in epithelial cells
AGS cells were grown as described above and were infected
with H. pylori 60190 at an MOI of 100. Six h after exposure, cell
supernatants were collected. IL-8 protein concentrations were
determined using a DuoSet human IL-8 ELISA kit (R&D Systems)
according to the manufacturer’s instructions.
Adherence of H. pylori to gastric epithelial cells
AGS cells and H. pylori 60190 were grown as described above
and cocultured at an MOI of 100 for 2 h with mild agitation every
20 minutes. Unbound bacteria were removed by washing three
times with PBS. The cells were then incubated at 37uC for 15
minutes with PBS containing 0.1% saponin to free AGS-associated
H. pylori. The bacteria were serially diluted and plated and colonies
were counted after 5 days of growth [30].
Protein expression in H. pylori
H. pylori 60190 was grown with or without 1% DFMO
supplementation for 12 h. An isogenic 60190 cagA
– mutant was
used as a control [31]. Bacteria were concentrated by centrifuga-
tion, washed with PBS and lysed in buffer containing 150 mM
NaCl, 1% NP40, and 50 mM Trizma-HCl (pH 8.0). 5 mgo f
protein were resolved by electrophoresis on a 4–20% Tris-HCl
polyacrylamide gel (Bio-Rad) and transferred overnight onto a
PVDF membrane, which was then blocked in 5% milk for 2 h.
CagA was detected with 1:2000 polyclonal anti-H. pylori CagA
antibody (Austral Biologicals) followed by 1:5000 horseradish
peroxidase-conjugated anti-rabbit secondary antibody (Jackson
ImmunoResearch). Urease was detected with 1:10,000 polyclonal
anti-H. pylori UreB antibody [32] followed by 1:5000 horseradish
peroxidase-conjugated anti-rabbit secondary antibody (Jackson
ImmunoResearch). Signals were detected using SuperSignal West
Pico peroxidase substrate (Thermo Scientific).
mRNA expression in H. pylori
H. pylori 60190 was grown for 6 h or 12 h. Total RNA was
extracted from 10
8 bacteria using TriZOL, and cDNA was
synthesized from 1 mg RNA. Real-time PCR was performed in a
LightCycler 480 (Roche). Relative gene expression was calculated
from second derivative maximum values using 16S rRNA as a
reference gene. cagA primers were 59-ACCAACAAGGTAA-
CAATGTGGC-39 and 59-TCGTTGTGAGCCTGTGAGTTG-
GT-39. cagE primers were 59-CAATGGGTGGGGAGTATGTC-
39 and 59-TGCTCCATTGTTGCATTTGT-39. cagM primers
were 59-GGTTGCGTTTGGAGTTTTGTCGGC-39 and 59-
AGCGTCTTCTTTTGCGGCCACT-39. 16S primers were 59-
CAGCTCGTGTCGTGAGATGT-39 and 59-CGTAAGGGC-
CATGATGACTT-39.
Determination of cagA transcript stability
H. pylori 60190 was grown with or without 1% DFMO
supplementation for 6 h at which time 100 mg/mL rifampicin
was added to halt RNA transcription. At 15 min intervals aliquots
of H. pylori containing 10
8 bacteria were removed, washed twice in
PBS and resuspended in TriZOL. Transcript levels of cagA were
determined by real-time PCR as described above and normalized
to stable 16S rRNA levels [33]. Transcript half-lives were
determined by fitting exponential decay curves to the data.
Detection of CagA translocation
2.5610
6 AGS cells were plated in 60-mm
2 tissue culture dishes
and were infected for 6 or 12 h at an MOI of 100 with H. pylori
60190 grown for 12 h, with or without DFMO. The cells were
removed by trypsinization and lysates were prepared by three 10-
second pulses of sonication at 40 W (Ultrasonic Processor GE
130PB, Hielscher) in buffer composed of 50 mM Tris-HCl
(pH 8.0), 150 mM NaCl, 1% (v/v) NP-40, and 0.1% (w/v)
sodium dodecyl sulfate. 25 mg of protein were resolved by
electrophoresis on 10% Tris-HCl polyacrylamide gels (Bio-Rad)
and transferred overnight onto PVDF, which was then blocked in
3% BSA for 1 h. Phosphorylated proteins were detected with
1:300 diluted anti-phosphotyrosine antibody (Santa Cruz Biotech-
nology) followed by 1:3000 horseradish peroxidase-conjugated
anti-mouse secondary antibody (Jackson ImmunoResearch).
Signals were detected using SuperSignal West Pico peroxidase
substrate. After antibody stripping (Restore Western blot stripping
buffer, Thermo Scientific) and reblocking in 5% milk, blots were
probed with 1:2000 polyclonal anti-H. pylori CagA antibody
(Austral Biologicals), followed by 1:3000 horseradish peroxidase-
conjugated anti-rabbit secondary antibody (Jackson ImmunoR-
esearch). As a loading control, b-actin levels were detected using
1:20,000 anti-b-actin antibody (Sigma) followed by 1:10,000 anti-
mouse secondary antibody (Jackson ImmunoResearch).
Urease activity assay
We used a modification of the method of Nagata, et al. to
measure urease activity in bacteria [34]. Briefly, H. pylori SS1 or
60190 were grown in Brucella broth with or without 1% DFMO.
After 3 or 6 h aliquots of bacteria were removed, washed in PBS
and rapidly frozen in liquid nitrogen. Bacteria (1610
6) were
incubated in a detection solution consisting of 0.0001% (w/v)
phenol red and 100 mM urea in PBS and OD550 readings were
taken over 60 min. Activity was determined from the slope of a
best-fit line on a plot of OD550 versus time and was normalized to
values obtained for control cultures.
Statistical analysis
Data are expressed as means 6 standard error. Student’s t test
was used for pairwise comparisons. Data from more than two
groups was analyzed by ANOVA followed by the Newman-Keuls
post hoc multiple comparisons test. The Kruskal-Wallis test
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bacterial size data.
Results
Growth of H. pylori is inhibited by DFMO
We recently reported that in mice infected with the mouse-
adapted strain H. pylori SS1, administration of 1% DFMO
suppressed both bacterial colonization and gastric inflammation
[6]. Notably, this is the same dose of DFMO that has been shown
to be efficacious in mouse models of colon tumorigenesis [35].
Although no sequenced H. pylori genome has been found to
contain an ODC, we investigated whether DFMO had any direct
effect on the bacterium. H. pylori are primarily found in the surface
mucous layer of the stomach, and we began with the assumption
that in our in vivo mouse model the 1% DFMO in the drinking
water would reach the H. pylori bacteria at this concentration, and
the DFMO is replenished continuously by ongoing intake of this
agent in the drinking water. Therefore, we initiated our studies
with 1% DFMO (55 mM) in liquid culture media. Flasks of broth,
some supplemented with different percentages of DFMO, were
inoculated with H. pylori SS1 at an OD600 of 0.1 and growth was
monitored by optical density for 24 h (Figure 1A). Growth of H.
pylori in broth containing 1% DFMO was restricted beginning 4 h
post-inoculation, while lower concentrations had no effect. When
we repeated these growth curves to quantify the inhibitory effects
of the chemical, we observed that H. pylori SS1 grown in standard
broth had a generation time of 4.1 h during the exponential
growth phase from 0–12 h (Figure 1B). In contrast, 1% DFMO
significantly increased the generation time to 7.3 h (p,0.001), an
increase of 78% (Figure 1B). We also monitored growth of H. pylori
by diluting and plating the bacteria at time points from 0 to 24 h.
At 8 h there were 3867% fewer viable, culturable bacteria and at
24 h there was an 8664% decrease (Figure 1C). These findings
indicated that there was a direct effect of DFMO on H. pylori that
was observable as a decrease in growth rate.
The mechanism of growth inhibition does not involve
polyamines
DFMO is an irreversible inhibitor of ODC, an enzyme in the
polyamine pathway of many organisms. However, as no
homologue of this enzyme has been identified by sequence
analysis in any H. pylori genome, we suspected that an alternative
mode of action was responsible for the effect of DFMO on these
bacteria. Although H. pylori contains no recognized ODC,
homologous enzymatic activity could still be present. We therefore
measured ODC activity in lysates of bacteria cultured with or
without 1% DFMO. In contrast to E. coli DH5a, which exhibited
substantial ODC activity, decarboxylation of ornithine in H. pylori
lysates was 93.862.3% lower (p,0.01) and was not affected by
DFMO (Figure 2A). In addition, polyamine levels measured in H.
pylori lysates and culture supernatants were unaffected by DFMO
treatment (Figures S1 and S2), suggesting that the mechanism of
action of DFMO does not involve alterations to polyamine
metabolism.
We next investigated if the inhibitory effect of DFMO on H.
pylori growth was shared by the amino acid ornithine, which has a
similar chemical structure. To test this, we compared H. pylori SS1
grown in broth supplemented with 1% DFMO or an equimolar
concentration of L-ornithine. The addition of L-ornithine had no
effect on the growth of the bacteria (Figure 2B).
The culture medium used to grow the bacteria—Brucella broth
plus 10% FBS—is a rich polyamine-containing medium and
analysis by HPLC indicated that it contained 4.94 mM putrescine
Figure 1. DFMO suppresses the growth of H. pylori. Brucella broth
cultures, some containing DFMO, were inoculated with H. pylori SS1 at
an OD600 of ,0.1 and growth was monitored for 24 h. (A) Bacteria were
grown in control broth or broth supplemented with 0.01%, 0.1%, or 1%
(w/v) DFMO and growth was monitored by measuring OD600 at the
indicated time points. Solid lines depict the growth curve obtained for
each treatment and error bars represent the standard error (n=3). (B) H.
pylori were grown and monitored as described for panel A in control
broth or broth with 1% DFMO. Solid lines are experimentally obtained
growth curves, with standard errors (n=9), while the dashed lines
indicate the calculated exponential regression curves using the first
12 h of data. The generation time (g) and goodness of fit (R
2) are
indicated for each curve. (C) Bacteria were cultured as in panel B, and at
the indicated time points samples were collected, diluted and plated on
solid medium. Colonies were counted once visible to calculate
concentrations of viable bacteria. Solid lines depict the growth curve
obtained for each treatment and error bars represent the standard
errors (n=3). For all graphs, *, p,0.05; **, p,0.01; ***, p,0.001 versus
the control condition.
doi:10.1371/journal.pone.0017510.g001
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growth kinetics to control levels by supplementation with even
higher levels of exogenous polyamines. We did not attempt
spermine supplementation, as it has been reported that this
polyamine is not present in H. pylori [36]. Attempts to counteract
the inhibitory effect of DFMO by addition of either 100 mM
putrescine (Figure 2C) or 100 mM spermidine (Figure 2D) had no
effect, and spermidine alone actually had a modest inhibitory
effect at 24 h. However, the reported absence of any identified
polyamine transporters in this bacterium [11] could account for
our observations.
DFMO does not inhibit the growth of other Gram-
negative bacteria
As our experiments to this point utilized a single strain of H.
pylori, SS1, and the H. pylori species is known to exhibit an extreme
degree of genetic diversity [37], we next investigated the growth
inhibitory effect of DFMO on a second strain of H. pylori, 60190,
that has been extensively used in laboratory studies [38,39]. When
we tested the effect of 1% DFMO on the growth of strain 60190
we observed a similar outcome, with generation time increasing
from 3.6 h to 7.8 h (Figure 3A). We then explored whether the
effect of DFMO was more universal and could be seen in other
bacterial species. We selected E. coli and C. rodentium, which are
Gram-negative bacteria of the same phylum as H. pylori
(Proteobacteria). Neither of these species were affected by 1%
DFMO, nor was there an effect when we doubled the
concentration to 2% (Figures 3B and 3C). The fact that no
inhibition of growth was observed using E. coli or C. rodentium, close
relatives of H. pylori that do express ODC, suggests that the effect
may be species-specific and is not simply due to toxicity, and that
the mechanism is likely polyamine-independent.
The effect of DFMO is not permanent
In our previous study, we reported that mice infected with H.
pylori SS1 and then treated continuously with 1% DFMO for 4
months demonstrated reduced colonization and gastritis. Our
current findings suggest that this effect could involve direct
alteration of bacterial metabolism as well as the known inhibition
of host cell ODC. In an attempt to separate these effects, we
infected mice with H. pylori cultured for 12 h with or without 1%
DFMO prior to inoculation, in the absence of in vivo treatment of
the animals, and quantified bacterial colonization after 1 month by
homogenizing a portion of the stomach and plating dilutions on
solid medium. We found no difference in the level of colonization
at this time point (Figure 4A), suggesting that the effect of DFMO
required continuous exposure to the chemical and that in the
absence of DFMO, H. pylori could return to its unaffected state. To
further examine the permanence of these effects we carried out
experiments in which bacterial cultures were begun in one
medium—either with or without 1% DFMO—and then switched
after 6 h of growth, a time point at which growth suppression and
metabolic perturbation is already apparent. Figure 4B illustrates
that cultures maintained in one medium (i.e. no DFMO, or
continuous DFMO) exhibited growth patterns identical to those
seen in earlier experiments. In addition, cultures begun in
unadulterated medium and then switched to broth containing
DFMO showed a nearly immediate reduction in growth rate.
Figure 2. Polyamine pathways are not involved in the growth-suppressive effect of DFMO. (A) Bacteria were grown for 6 h with or
without 1% DFMO, then washed and lysed by sonication. Lysates were incubated with
14C-labeled ornithine and ODC enzyme activity was
determined by quantification of released
14CO2, normalized to total protein level and time, after subtracting lysate-free background values. **,
p,0.01; ***, p,0.001 versus activity in E. coli. (B), (C), (D) Cultures were supplemented as labeled and grown and monitored by OD600 as described for
Figure 1 (n=3). For panels B, C and D,* ,p,0.05; ***, p,0.001 versus the control condition. Put, putrescine; Spd, spermidine.
doi:10.1371/journal.pone.0017510.g002
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that were then switched to plain medium at 6 h were able to
recover very quickly, so that by 12 h of additional growth they had
attained the same growth rate as the cultures continuously grown
without DFMO (generation time of 4.4 h vs. 4.5 h, p=0.363).
This rapid resurgence suggested that rather than being killed by
exposure to DFMO, the chemical instead had a bacteriostatic
effect. When we repeated these experiments with switching
delayed until 12 h had elapsed (Figure 4C) the results were
similar, except that those H. pylori transferred from 1% DFMO to
control medium exhibited a lesser ability to recover compared to
bacteria switched after 6 h. After 12 h of additional growth,
generation time in continuous control medium was 7.0 h while
that in the cultures switched from DFMO to normal medium was
only 9.2 h (p=0.0502).
DFMO alters cell morphology
Due to the manner of bacterial replication, via binary fission,
growth rate can be linked with bacterial size. We therefore
determined if DFMO induced any alterations in bacterial
morphology. To test this, we sampled bacteria from the 6 h
switching experiment and performed Gram stains at 6 h after the
medium switch. The bacteria from cultures containing 1% DFMO
appeared to be smaller than bacteria from cultures without
DFMO (Figure 5A). Due to the low resolution afforded by light
microscopy, we also prepared samples of bacteria for transmission
electron microscopy. Sections of bacterial pellets were examined
(Figure 5B) and the sizes of individual bacteria were determined
using NIH ImageJ software. As was suspected from the Gram
stains, bacteria cultured in the presence of 1% DFMO were
significantly smaller than those cultured in plain broth (p,0.001).
We also observed that 6 h after removal of DFMO bacterial size
had significantly increased (p,0.001), and that 6 h of culture with
DFMO after switching was sufficient to significantly reduce
bacterial size (p,0.001) (Figure 5C). These data indicate that H.
pylori morphology is rapidly altered by exposure to DFMO, but
that the effect disappears once the chemical is removed.
The discovery that bacterial morphology was altered by
exposure to DFMO caused us to reexamine our investigations
using optical density, as such measurements could be dependent
on bacterial size and shape. To allay these concerns we plotted
bacterial concentration (CFU/mL) versus OD600 for bacteria
grown with or without 1% DFMO for up to 12 h (Figure 5D).
When constrained to pass through the origin, linear regression
analysis of the two data sets found no significant difference
(p=0.595) and revealed that an OD600 of 1 was equivalent to
8.11610
8 CFU/mL. This finding indicates that the changes in
bacterial size did not affect the estimations of bacterial
concentration, and thus the growth curve data reported above
required no reanalysis.
DFMO affects bacterial metabolism
Monitoring bacterial growth by optical density has inherent
limitations, as both live and dead cells can remain in suspension
and contribute to an apparent increase in the number of growing
bacteria. We attempted to circumvent this problem by quantifying
viable cells by diluting and plating the culture on solid medium.
Although we did begin to see a decrease in the number of
culturable bacteria after 8 h of culture (Figure 1C), optical density
levels diverged 4 h prior (Figure 1B) and significant die-off of H.
pylori was not seen until 24 h of culture with 1% DFMO. Our
inference was that rather than having a bactericidal effect, DFMO
was altering cell metabolism, which led to a significant decrease in
growth rate. To determine if this was the case, we utilized a
luciferase-based assay to measure ATP levels in bacterial lysates.
Unexpectedly, rather than inducing a decrease in ATP, DFMO
had the opposite effect. When we analyzed equal volumes of
cultures grown with or without 1% DFMO, we observed a
significant increase in ATP levels beginning only 1 h after
initiation (Figure 6A). ATP levels per microliter increased steadily
Figure 3. DFMO affects H. pylori 60190, but has no effect on two
other Gram-negative bacteria. (A) Growth rates of H. pylori 60190
cultured in the absence or presence of 1% DFMO were compared as
described in Figure 1B. Dashed lines indicate exponential curve
regressions for each data set and are labeled with generation time
and goodness of fit (n=3; *, p,0.05). (B) E. coli DH5a were grown in
control broth or broth supplemented with 1% or 2% DFMO and growth
was monitored for 8 h. (C) C. rodentium were grown in control broth or
broth supplemented with 1% or 2% DFMO and growth was monitored
for 8 h.
doi:10.1371/journal.pone.0017510.g003
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DFMO-containing cultures leveled off. For control bacteria there
was obvious parallelism between the ATP levels and the OD600
growth curve shown in Figure 1B, but this was not seen for
bacteria exposed to DFMO. As ATP levels can be used as a
surrogate measure of cell numbers—for comparably grown
cultures—we presumed that the observed increase simply
indicated continued growth of H. pylori. To eliminate this
uncertainty we used the optical density of the cultures, and the
equation derived from Figure 5D, to calculate the ATP-dependent
luminescence per 10
6 bacteria. This transformation demonstrated
that the effect of DFMO was even greater than initially perceived.
When compared to control cultures, DFMO induced a 1.5-fold
increase in luminescence by 1 h that grew to 3.4-fold by 12 h
(p,0.001; Figure 6B). We also observed that while the control
culture maintained a relatively steady level of ATP/10
6 bacteria
throughout the entire time course (405.8628.8 luminescence
units), large dynamic changes were seen in the 1% DFMO
cultures, suggesting that the chemical drastically altered the
metabolism of H. pylori.
DFMO reduces the proinflammatory effect of H. pylori
Acute active inflammation characterized by neutrophil infiltra-
tion is a central constituent of the immune response to H. pylori
infection. Chemokines, which are secreted chemoattractant
proteins, are responsible for the influx of these cells to the site of
infection. IL-8 is one such chemokine, and its expression has been
reported to be increased in the gastric mucosa of infected patients
[16,17,40] and in gastric epithelial cells inoculated with H. pylori in
vitro [41,42]. We cocultured human gastric epithelial AGS cells
with H. pylori 60190, a strain known to induce IL-8 in these cells
[43] at an MOI of 200 for 4 h and then analyzed mRNA levels
(Figure 7A). H. pylori 60190 induced a 145.169.5-fold increase in
IL-8 mRNA expression compared with untreated cells (p,0.001)
and this induction was nearly halved when bacteria cultured in the
presence of 1% DFMO for 12 h prior to addition to host cells were
used (73.469.4-fold, p,0.001). We also measured IL-8 protein
levels in supernatants of AGS cells cocultured with H. pylori 60190
at an MOI of 100 for 6 h (Figure 7B). Cells infected with bacteria
grown without DFMO produced 33166392 pg/mL IL-8, a
7.262.5-fold increase over control cells (p,0.001). When H. pylori
cultured in the presence of 1% DFMO were used, AGS cells
generated only 20666316 pg/mL IL-8, a 47.866.7% inhibition
(p,0.01). These data suggest that the immunostimulatory effect of
the bacteria is lessened by exposure to DFMO.
Some studies have reported that coccoid-form H. pylori exhibit
reduced adherence compared to helical-shaped bacteria and that
this correlates with lesser induction of IL-8 [44,45]. To determine
if a similar effect occurred with the bacteria altered by DFMO, we
compared adherence to AGS cells of H. pylori grown with or
without 1% DFMO for 12 h. There was not a decrease, but rather
there was a modest increase in adherence, with 1.0160.22% of
untreated bacteria and 1.7560.33% of DFMO-treated bacteria
found to be adherent, respectively (Figure 7C). Thus, the
differential induction of IL-8 was likely due to induced changes
in the bacteria and not simply disparities in adherence.
CagA expression and translocation are affected by DFMO
H. pylori possesses a number of virulence factors known to be
important for the induction of disease during infection. One of the
best described is the effector molecule CagA, which has been
implicated in the disruption of tight junctions and alteration of
cellular morphology [46]. As infection with CagA-expressing
strains of H. pylori is associated with worse clinical outcome in
patients, namely higher rates of peptic ulcer disease and gastric
cancer [46,47,48,49], we sought to determine if DFMO treatment
could affect the production and function of this bacterial protein.
We utilized H. pylori 60190 in this set of experiments, since it has
been reported that SS1 has an incomplete cag pathogenicity island
(cag-PAI) [50]. Bacteria cultured for 12 h in the presence of 1%
DFMO exhibited lower levels of CagA protein expression
compared to untreated cells (Figure 8A). This effect was not due
to a global suppression of protein translation, as levels of UreB, a
Figure 4. The effect of DFMO on H. pylori requires constant
exposure. (A) Mice were infected with H. pylori SS1 grown for 12 h
with or without 1% DFMO and colonization levels were determined
after one month. Each point represents bacterial load in a single mouse,
and mean and standard error are indicated (n=12 per group). (B)
Growth curves were performed to determine the permanence of the
effect of DFMO. Brucella broth cultures, with or without DFMO, were
inoculated with H. pylori. After 6 h, the cultures were centrifuged and
switched to new medium so that four conditions resulted: –DFMO R
–DFMO, +DFMO R –DFMO, –DFMO R +DFMO, and +DFMO R +DFMO.
Bacterial levels were monitored by OD600. Data depicted are from a
single representative experiment; similar results were obtained in two
others. (C) Conditions are the same as for panel B, except that medium
switching occurred after 12 h of growth. Data are from a single
representative experiment of three performed.
doi:10.1371/journal.pone.0017510.g004
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affected. Although we observed a decrease in CagA protein,
mRNA levels were not affected by DFMO (Figure S3A), indicating
that it acts in a post-transcriptional manner. This type of control of
expression, which can involve altered mRNA stability, has been
reported for other H. pylori genes [51,52,53]. We measured the
stability of cagA from cultures grown with or without DFMO, but
did not observe any increase in decay rate; in fact, we found that
DFMO improved transcript stability and increased its half-life
from 3.4 min to 4.3 min (Figure S3B).
CagA translocation is required in order for the protein to exert
its effects on host cells [18], and once within the host cytoplasm
CagA can be phosphorylated by tyrosine kinases [54,55]. Figure 8B
demonstrates that lysates of AGS cells infected with H. pylori grown
with 1% DFMO prior to coculture with the host cells for 6 h
contained lower levels of CagA protein and phosphorylated CagA
(identified as a tyrosine-phosphorylated protein of ,130 kDa) [56]
than lysates of cells infected with control bacteria. When assessed
after 12 h of coculture with AGS cells, the levels of CagA protein
in lysates from AGS cells infected with H. pylori grown with
DFMO had recovered, but the levels of phosphorylated CagA had
not (Figure 8C). Differences in levels of phosphorylated CagA
could indicate disruption of the T4SS responsible for its
translocation. However, when we measured mRNA levels of cagE
and cagM, two members of the cag-PAI that are essential
components of the T4SS, exposure to DFMO for either 6 h or
12 h had no effect on the levels of these transcripts (Figures S3C
and S3D). Taken together, these data indicate that exposure to
DFMO affects the ability of H. pylori to produce and translocate
CagA, a major virulence factor, adding to its potential as an
antibacterial agent.
Discussion
H. pylori is a major cause of mortality and morbidity worldwide.
It is estimated that more than 50% of the human population is
infected, with higher prevalence in the developing world and less
in industrialized countries [57,58]. Most infections induce only
mild gastritis, but if left untreated they can lead to gastric and
duodenal ulceration or gastric cancer. Standard treatment
regimens are known to be far less than 100% effective
[3,4,5,59], indicating that novel therapies could be useful,
especially given high rates of antibiotic resistance worldwide
[59]. In our recent publication on the protective effect of DFMO
administration on H. pylori-induced gastritis in mice—indicated by
reduced inflammation and colonization—we concluded that it was
attributable to the beneficial effects of the chemical’s inhibition of
host ODC activity [6]. In the current report we have
demonstrated that a direct effect of DFMO on the bacteria may
also be important.
Our data indicate that exposure to 1% DFMO suppresses
growth of H. pylori such that generation time is nearly doubled.
The mechanism of action does not appear to involve polyamine
synthesis since there was no detectable ornithine decarboxylase
Figure 5. DFMO alters bacterial morphology. Bacterial samples were removed from cultures 6 h after the medium switch depicted in Figure 4B.
Gram stains were performed and examined by light microscopy (A) and bacterial pellets were fixed, sectioned, and stained for TEM (B). Note that the
labels for panel A also apply to panel B. Scale bars indicate 2 mm in panel A and 1 mm in panel B. (C) Stained bacteria were examined by TEM and
cross-sectional areas were measured. For each treatment group the box identifies the median and 25
th and 75
th percentile values and the whiskers
indicate the range of measurements (n=83–129 measurements per group). ***, p,0.001 between groups indicated. D, a plot of OD600 versus
bacterial concentration in CFU/mL was created from the data points of the first 12 h of growth curves depicted in Figures 1B and 1C (n=9 per
treatment). The lines illustrate the best-fit linear regression of each treatment group (control, solid line; 1% DFMO, dashed line) constrained to pass
through the origin. The two lines did not significantly differ (p=0.595). The global best-fit line (not depicted, R
2=0.80) indicated that an OD600 of 1
was equivalent to 8.11610
8 CFU/mL.
doi:10.1371/journal.pone.0017510.g005
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polyamine products was unable to reverse the effect. In addition,
other Gram-negative bacterial species that do contain ODC were
found to be insensitive to the inhibitory effect of DFMO. This lack
of effect on other bacteria suggests that the DFMO is not overtly
toxic at this dose. Additionally, the concept that the action of
DFMO was not a result of direct toxicity of the chemical was
supported by our finding that H. pylori were not immediately killed,
and in fact responded with increased ATP levels. We found that
the induced alterations required continuous exposure to DFMO
and were reversible by halting exposure. We also noted that the
alterations to growth rate and metabolism could be observed as a
change in bacterial morphology, with DFMO causing the H. pylori
to adopt a more coccoid form. These altered bacteria expressed
lower levels of CagA, translocated less CagA, and induced 50%
less IL-8 expression in gastric epithelial cells than untreated
bacteria, despite there being no difference in adherence to these
epithelial cells in vitro.
In order to affect growth of H. pylori a high concentration of 1%
DFMO (equivalent to 55 mM) was required. This dose was the
same as was administered to mice ad libitum in our previous study
[6]. Given that a mouse weighs between 20 and 25 g and
consumes 10–15 mL of water daily, this implies that each mouse
receives a daily DFMO dosage in the range of 4000–7500 mg/kg.
Allometric dose translation [60] for human administration would
be approximately 500 mg/kg. Although this dose is high, similar
or higher levels have been used for treatment of trypanosomiasis,
via inhibition of the parasite’s ODC. Clarkson et al. [61] cured
experimentally infected mice with a 14-day course of 2% DFMO
and a single dose of the anti-protozoal agent suramin. The same
group also reported that late-stage human sleeping sickness could
be cured by 14 days of intravenous 400 mg/kg DFMO followed
by 3–4 weeks of oral dosage at 300 mg/kg [62]. Although there
were side effects at this dosage, including diarrhea and abdominal
pain, all were reversible, and treatment of H. pylori would likely not
require such a lengthy period of treatment.
Previous studies have indicated that exposure of E. coli or
Pseudomonas aeruginosa to the polyamine synthesis inhibitors
monofluoromethylornithine, difluoromethylarginine, and dicyclo-
hexylammonium sulfate significantly increased bacterial genera-
tion times and could be overcome by addition of exogenous
polyamines [63,64]. However, the inhibitory effect on H. pylori
growth likely involves an alternative mechanism, as the genome of
this species contains no recognized ODC gene, and the bacteria
Figure 6. Metabolic activity is altered in H. pylori cultured with
1% DFMO. Cultures were grown for 24 h and bacterial samples were
removed at the indicated time points. Relative ATP levels were
measured in bacterial lysates using CellTiter-Glo, a luciferase-based
assay kit. (A) Luminescence (Lum) units, proportional to ATP
concentration, were calculated for equivolumetric samples. (B) Lumi-
nescence units per 10
6 bacteria at each time point were calculated
using the data from panel A, the observed OD600 of the culture, and the
equation derived from Figure 5D. Each data point is the average of 3
experiments with the standard errors shown. For both graphs, *,
p,0.05; **, p,0.01; ***, p,0.001 versus the control condition.
doi:10.1371/journal.pone.0017510.g006
Figure 7. DFMO-treated H. pylori 60190 induce less IL-8 expression. Human gastric AGS cells were exposed to strain 60190 previously grown
for 12 h with or without 1% DFMO and IL-8 expression was determined. (A) Real-time PCR was used to measure levels of IL-8 mRNA after 4 h of
exposure. Bars indicate the mean level of gene expression relative to uninfected control cells (n=3). (B) IL-8 protein levels in supernatants were
measured by ELISA after 6 h of infection. Bars indicate the mean IL-8 concentration (n=6). (C) After 2 h of infection adherent bacteria were quantified
by serial dilution and plating. Each point is a single well of AGS cells and the means and standard errors are depicted (n=8). **, p,0.0; ***, p,0.001
versus the control condition; 11, p,0.01; 111, p,0.001 versus cells infected with untreated bacteria.
doi:10.1371/journal.pone.0017510.g007
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and C. rodentium, two bacterial species that do possess an ODC,
were completely insensitive to the inhibitory effects of DFMO.
The polyamine pathways of H. pylori are not completely
understood and may be unique, as the species is missing a number
of biosynthetic enzymes found in other bacteria [12,13,14,15]. In
addition, the sequenced genomes of H. pylori contain no
recognizable polyamine transporters. It has been suggested that
in the high-acid environment of the stomach all polyamines would
be completely protonated and therefore unable to be acted on by
known polyamine binding proteins [11]. In our experiments,
DFMO had no effect on intracellular or extracellular polyamine
levels of bacterial cultures and supplementation with either
putrescine or spermidine did not restore the growth rate to
normal levels. Although none of our findings indicate the
involvement of polyamine metabolism in the mechanism of action
of DFMO on H. pylori, others have targeted polyamine synthesis in
this bacterium using methylglyoxal bis(cyclopentylamidinohydra-
zone) (MGBCP), an inhibitor of multiple enzymes, including
spermidine synthase [65]. Exposure to MGBCP caused a dramatic
reduction in the growth of H. pylori in vitro, but the authors
suggested that the localization of H. pylori within the mucus layer of
the highly acidic stomach could limit its chemotherapeutic
effectiveness. Our previous study [6] indicates that DFMO is
effective in vivo in a mouse model when administered continuously
after inoculation with H. pylori.
In our recently published report we noted that treatment of H.
pylori-infected mice with DFMO led to decreased colonization via
enhanced antimicrobial nitric oxide generation by host macro-
phages, which we attributed to the drug’s effect on host cell ODC
that can otherwise inhibit translation of inducible nitric oxide
synthase [6]. The current study suggests that direct effects of
DFMO on the bacteria may play a role as well. When we
attempted to separate these two effects by infecting mice with H.
pylori SS1 pre-treated with DFMO for 12 h, after 1 month of
infection without treatment of the mice with DFMO, there was no
observable difference in colonization. We attributed this to the
rapid recovery of the bacteria once they were in the mouse
stomach and no longer exposed to DFMO, a supposition that was
supported when we performed growth curves in which we
removed DFMO supplementation from growing bacterial cultures
and observed the swift improvement of growth rate to normal
levels. In the future we will determine the relative importance of
the drug’s effects on the bacteria and host by administering
DFMO to heterozygous ODC
+/2 mice [66,67], which we will use
because homozygous deletion of ODC is lethal [8]. If the reduced
gastritis and colonization are recapitulated in infected ODC
+/2
mice, and if there is an even greater reduction with DFMO
treatment, this could suggest that drug effects on the bacteria are
important for its ameliorative properties.
H. pylori morphologic form may have a bearing on to its viability
and infectivity, but the literature on H. pylori coccoid forms is not
consistent. Coccoid forms were observed in one prospective study
of human gastric biopsies in 83% of cases [68] and it has been
suggested that they may provide a source for the spread of
infection or of recrudescence in patients reportedly cured [69].
Other reports on coccoid forms have reached a variety of
conclusions: that coccoid bacteria are a manifestation of cell
death [70]; that they are a viable, but non-culturable form [71];
that coccoid forms can successfully infect mice [72,73]; and that
they are unable to colonize neonatal pigs [74]. Irrespective of the
controversy surrounding the nature of coccoid bacteria, the
morphologically altered H. pylori we observed may differ from
those seen in other studies. The changes we report here occur very
rapidly, after only 6 h of exposure to DFMO, while other studies
induced coccoid forms by multi-day culture or exposure to
antibiotics [72]. In addition, whereas some have noted a decrease
in cellular activity following conversion of H. pylori to a coccoid
form [70], we measured higher internal levels of ATP after DFMO
treatment. This observed increase could indicate an upregulation
of ATP production or a downregulation of ATP usage leading to
an accumulation of the molecule. The latter seems more likely as it
correlates with the decrease in growth rate that we demonstrated.
Another recent discovery is that the state of peptidoglycan
crosslinking in H. pylori plays an important role in maintaining
its helical shape that is important in its motility and infectivity [75].
While knockouts of cell shape determinant (csd) genes did not affect
growth in vitro in that study, it still could prove important to
investigate the effects of DFMO on peptidoglycan and associated
csd genes in future experiments.
Increased expression of IL-8 is part of the immune response to
H. pylori infection in vivo [40]. As the known interaction of DFMO
with host cells prevents discrimination of the effect of DFMO on
Figure 8. DFMO suppresses H. pylori CagA expression and its
translocation into gastric epithelial cells. H. pylori strain 60190 was
grown for 12 h with or without DFMO supplementation. (A) Western
blot analysis of CagA and UreB expression in bacteria. An isogenic
60190 cagA mutant was used as a control. (B) Western blot analysis of
total CagA, tyrosine-phosphorylated CagA, and b-actin in lysates
prepared from AGS cells infected for 6 h with these bacteria or
uninfected as a control. (C) Western blot analysis of total CagA, tyrosine-
phosphorylated CagA, and b-actin in lysates prepared from AGS cells
infected for 12 h or controls.
doi:10.1371/journal.pone.0017510.g008
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the human gastric AGS cell line in the absence of DFMO in the
cocultures and observed that IL-8 expression was significantly
reduced. Some studies using coccoid-form bacteria have reported
that they induce lower levels of IL-8 in epithelial cells, and,
concomitantly, adhere to a lesser degree than helical H. pylori
[44,45]. Our data indicate no loss of adherence of DFMO-treated
bacteria, suggesting that other alterations of bacterial physiology
are responsible for the reduction in IL-8 expression. Production of
the chemokine IL-8 by the gastric epithelium elicits an influx of
neutrophils that are the hallmark of the acute gastritis associated
with H. pylori infection [46,47,76]. Thus, administration of DFMO
to patients could lead to reduced IL-8 expression by epithelial cells
and a reduction of inflammation.
Urease is an important virulence factor of H. pylori.I ti s
responsible for the hydrolysis of urea into ammonia that acts to
rapidly neutralize the low pH of the acidic stomach environment.
We utilized UreB, a subunit of the urease enzyme, as a control in
our bacterial Western blots and noted no decrease in its expression
with DFMO exposure. To further investigate if urease was affected
by DFMO, we measured enzymatic activity in both H. pylori SS1
and 60190. Consistent with the Western blot results, DFMO had
no effect on the urease activity after either 3 or 6 h of culture
(Figure S5).
The cag-PAI comprises a set of virulence genes encoding the
components of a T4SS able to deliver bacterial products into host
cell cytoplasm. The bacterial effector protein CagA is encoded
within the cag-PAI and when introduced into epithelial cells it
triggers a variety of signaling events that affect host cell processes
[46,47]. Some reports have indicated that IL-8 production by
AGS cells is CagA-dependent [77,78], though it should be
recognized that other studies have reported a CagA-independent
induction of this chemokine [43,79]. We observed that bacteria
grown in media containing 1% DFMO exhibited decreased CagA
protein expression and that AGS cells incubated with such
bacteria contained lower levels of phosphorylated CagA, indicat-
ing an additional potential benefit for the chemotherapeutic use of
this drug. Interestingly, prolonged coculture of H. pylori with AGS
cells led to recovery from the DFMO-induced suppression of total
CagA protein levels so that after 12 h no difference remained.
Since the phosphorylated form of CagA is found only inside AGS
cells, while total CagA levels are indicative of both the translocated
protein and that remaining in the bacteria adherent to the
epithelial cells, our data indicate that the effect of DFMO on CagA
expression dissipates more rapidly during the recovery of H. pylori
in AGS medium than does its effect on phospho-CagA levels. The
persistent inhibition of CagA phosphorylation may be due to
inhibition of translocation of CagA via post-transcriptional effects
on genes involved in the T4SS. In addition, we have found that
AGS cell culture medium poorly supports H. pylori growth, and it is
much more restrictive than Brucella broth (Figure S4), and thus it
is possible that the apparent normalization of CagA levels are part
of an overall stress response that overshadows the effect of DFMO.
Our data suggest that DFMO alters CagA expression via a post-
transcriptional mechanism. Such control has been reported for
other H. pylori genes including the flagellar protein FlaA [51],
neutrophil activating protein (Nap) A [52], and the global
regulator HP1043 [53]. FlaA protein levels are partially regulated
by destabilization of the flaA mRNA transcript [51], but when we
measured stability of cagA from cultures grown with or without
DFMO there was no increase in decay rate that could account for
the decreased level of CagA protein. It should be noted that while
some human patients are infected with cagA
– strains [46,47,48,49],
DFMO is likely to still have beneficial effects in such people,
because of its growth inhibitory effects. It is also likely that other
effects on H. pylori genes could be occurring, which could be
addressed by discovery studies using proteomic or microarray
analyses.
Although we have not determined the molecular mechanism by
which DFMO suppresses H. pylori growth, this drug may be a
useful adjunctive treatment for human H. pylori infections. DFMO
is used as treatment for trypanosomiasis, as mentioned above, and
oral DFMO (500 mg daily) has been found safe and effective as
part of a chemopreventive regimen for recurrent colorectal
adenomas [80]. To our knowledge, there are no reports on the
usage of DFMO as an antibacterial agent in vivo, despite the fact
that interference with the polyamine biosynthetic pathways could
be an attractive target for retarding fast-growing infections.
Although we would not suggest its use as a monotherapy, DFMO
treatment could be considered as a future addition to current
standard regimens, especially in regions of the world where H.
pylori exhibits high levels of antibiotic resistance.
Supporting Information
Figure S1 Polyamine levels in growth medium are
unaffected by DFMO. H. pylori SS1 were grown with or
without 1% DFMO and growth medium samples were taken over
12 h. Putrescine (A), spermidine (B), and spermine (C) levels were
determined by HPLC. The dashed line in each panel denotes the
polyamine level measured in uninoculated broth. Each point
represents the mean and standard error (n=3).
(TIF)
Figure S2 Polyamine levels in H. pylori are unaffected
by DFMO. H. pylori SS1 were grown with or without 1% DFMO
and bacteria were sampled over 12 h. HPLC was used to measure
spermidine (A) and spermine (B) levels in bacterial lysates (1610
7
H. pylori in 400 mL buffer). Each point represents the mean and
standard error (n=3).
(TIF)
Figure S3 DFMO does not affect cag transcript levels or
cagA mRNA stability. H. pylori 60190 were grown with or
without 1% DFMO for 6 or 12 h. mRNA levels of cagA (A), cagE
(C), or cagM (D) were determined by real-time PCR. Bars indicate
the mean level of gene expression relative to uninfected control
cells at each time point (n=3). (B) cagA mRNA stability was
determined by adding the transcription inhibitor rifampicin to H.
pylori cultures grown for 6 h. Transcript levels were quantified at
15 min intervals by real-time PCR and transcript half-lives (l)
were calculated by plotting an exponential decay curve to each
data set. Each point represents the mean and standard error of the
remaining cagA transcript compared to the 0 min time point as a
percentage (n=3).
(TIF)
Figure S4 H. pylori growth is stunted in AGS cell
medium. Cultures of F12 medium, some containing 1% (w/v)
DFMO, were inoculated with H. pylori SS1 at an OD600 of ,0.1
and growth was monitored for 24 h by measuring OD600 at the
indicated time points. Solid lines depict the growth curve obtained
for each treatment and error bars represent the standard error
(n=3), while the dashed lines indicate the calculated exponential
regression curves using the first 12 h of data. The generation time
(g) and goodness of fit (R
2) are indicated for each curve.
(TIF)
Figure S5 DFMO does not affect urease activity in H.
pylori. H. pylori SS1 (A) and 60190 (B) were grown with or
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pylori were flash frozen in liquid nitrogen then 1610
6 were
incubated for 60 min in a detection solution containing urea and
phenol red. Activity was determined from the slope of a best-fit
line on a plot of OD550 versus time. Bars indicate the mean urease
activity relative to the control cells at each time point (n=3).
(TIF)
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